Pernix Therapeutics Cash Flow - Annual (NASDAQ:PTX)

Add to My Stocks
$2.49 $0.04 (1.63%) PTX stock closing price Jun 18, 2018 (Closing)

The financial analysis of PTX requires an investor to check the cash flows for Pernix Therapeutics. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Pernix Therapeutics profits and Pernix Therapeutics debt. Pernix Therapeutics saw a cash impact of $1.97M from the issuance of PTX shares. The cash flow statement helps in the Pernix Therapeutics stock analysis by providing more information for evaluating changes in assets, liabilities and equities. Pernix Therapeutics has a negative cash and cash equivalents change of $-3.55M.

View details of Pernix Therapeutics cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-77.14M-169.59M-148.31M-35.28M-25.63M-1.41M8.34M9.3M-0.52M-0.53M
Depreciation Depletion Amortization Cash-Flow81.91M92.24M99.71M35.33M9.97M3.2M2.3M1.23M--
Net Increase (Decrease) in Assets Liabilities-3.5M22.73M-4.23M10.48M21.84M-5.48M-1.77M-2.39M--0.38M
Cash From (used in) Discontinued Operations---------1.02M-
Other Adjustments Net-7.2M38.1M38.09M-1.63M-12.71M1.76M--3.48M--1.34M
Net Cash from (used by) Operating Activities
-5.93M-16.5M-14.74M8.89M-6.53M-1.92M9.39M4.66M-1.23M-2.26M
Increase (Decrease) in Prop Plant And Equipment-0.01M-0.98M-1.21M-1.13M19.09M-0.31M-0.17M-0.11M--0.01M
Acquisition Disposition of Subsidiaires--0.58M-87.98M-253.81M-0.3M-63.72M--3.82M--
Increase (Decrease) in Investments----4.6M--2M-1.5M--
Other Cash Inflow (Outflow) from Investment Activities2M-4.85M5.02M--0.85M--0.25M-2.23M
Net Cash from (used by) Investment Activities
1.98M-1.56M-84.34M-249.92M23.38M-64.89M-2.17M-5.69M-2.21M
Issuance (Purchase) of Equity Shares1.97M19.81M-2.3M-24.58M19.54M-0.77M--
Issuance (Repayment) of Debt Securities11.93M-20.48M119.94M284.95M-12.64M39.93M----
Increase (Decrease) in Bank & Other Borrowings--1M7.65M-9.51M-12.65M-6M1M5M--
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-13.69M-0.02M-7.61M-17.5M--3.22M-1.47M---
Net Cash from (used by) Financing Activities
--1.69M120.37M260.23M-24.23M55.29M19.06M4.71M--
Effect of Exchange Rate Changes on Cash---------0.04M-
Net Change in Cash & Cash Equivalents
-3.55M-19.76M21.28M19.2M-7.37M-11.52M26.29M3.68M-1.28M-
Cash & Equivalents at Beginning of Year36.37M56.13M34.85M15.64M23.02M34.55M8.26M4.57M8M7.39M
Cash & Equivalents at Year End32.82M36.37M56.13M34.85M15.64M23.02M34.55M8.26M6.71M8M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Pernix Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Pernix Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:

  • Pernix Therapeutics had a Net Change in Cash and Cash Equivalents of $-3.55M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Pernix Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-5.93M for PTX.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $1.98M for PTX stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $- for Pernix Therapeutics.

Key Financial Ratios For Pernix Therapeutics Cash Flow

Annual Cash Flow Statements For Pernix Therapeutics Holdings Inc Peers

Cumberland Pharma cash flow, Depomed cash flow, Evoke Pharma cash flow, Vanda Pharmaceuticals cash flow, Versartis cash flow